STRIDES ARCOLAB LTD Bannerghatta, Bangalore, Karnataka

Strides Arcolab Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine Tablets USP, 150 mg300 mg.

For improvement of post prandial hyperglycemia in diabetes mellitus, when only diet andor exercise or oral hypoglycemic drugs or insulin preparation in addition to diet andor exercise do not result in adequate glycemic control.a day, before each meal. If the effect is not sufficient, the quantity of a single dose

The core generic pharma business of Strides is led by IP-driven product licensing and marketing and distribution partnerships across the globe. We have leveraged our expertise in niche, difficult-to-develop and manufacture products to emerge as a preferred provider of solutions to global pharma majors. Strides has created an exhaustive pipeline of generics across varied formats and domains including oral dosage forms and topicals. We are one among the leading players worldwide in soft gel capsules.

Our domain strategy of developing a comprehensive product portfolio in complex therapeutic segments such as immune-suppressants, anti-virals, high-end antibiotics has attracted marquee partnerships in Regulated markets such as US, UK, Australia and S. Africa. The partnerships we have forged with major pharma players have provided an opportunity for Strides to play an increasingly important role in the global pharma industry. As a next step Strides is enhancing its front-end operations in US and UK to be better positioned to seize new opportunities.

Alfacalcidol is indicated in conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function. The main indications are: a) Renal osteodystrophy b) Hyperparathyroidism (with bone disease) c) Hypoparathyroidism d) Neonatal hypocalcaemia e) Nutritional and malabsorptive rickets and osteomalacia f) Pseudo-deficiency (D-dependent) rickets and osteomalacia g) Hypophosphataemic vitamin D resistant rickets and osteomalacia